Product Program year 2019 Source: CMS Open Payments

Cosentyx_Cosentyx_Dermatology

Biological Dermatology

NDC 0078-0639-41

Open in the dashboard

General payments

$119,214

54 payments

Research payments

$0

0 payments

Through program year 2019, $119,214 in general payments and $0 in research payments were reported against Cosentyx_Cosentyx_Dermatology (Dermatology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2019 General $119,214 54

Breakdown

Who paid General payments · program year 2019
  1. Novartis Pharma AG $119,214 54 payments
Top recipients General payments · program year 2019
  1. Surya Singh Internal Medicine · Boston, MA $19,290 16% · 4 payments
  2. Mark Genovese Rheumatology · Stanford, CA $17,011 14% · 7 payments
  3. Philip Mease Rheumatology · Seattle, WA $14,406 12% · 9 payments
  4. Marina Magrey Internal Medicine · Cleveland, OH $13,585 11% · 9 payments
  5. Anthony Turkiewicz Rheumatology · Mountain Brk, AL $10,864 9% · 4 payments

The top 5 of 11 recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Rheumatology Internal Medicine $70,891 63% · 7 practitioners
  2. Internal Medicine $32,875 29% · 2 practitioners
  3. Dermatology $9,000 8% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2019
  1. California $21,554 18% · 2 recipients
  2. Massachusetts $19,290 16% · 1 recipient
  3. New York $16,810 14% · 2 recipients
  4. Washington $14,406 12% · 1 recipient
  5. Ohio $13,585 11% · 1 recipient

The top 5 of 9 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

109

Prescriptions dispensed, refills included

Drug cost

$432,282

Paid at the pharmacy, in all

Prescribers

4

With 11 or more claims of it

Medicare Part D drugs matched to COSENTYX_COSENTYX_DERMATOLOGY, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Cosentyx Secukinumab Similar name 4 109 $432,282

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

4 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Samy Metyas Rheumatology CA 41 $155,086 None on record
Carolyn Pace Rheumatology AZ 28 $110,442 None on record
Elvin Garcia Rheumatology TX 26 $120,959 None on record
Ramon Moreda Rheumatology FL 14 $45,795 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

54 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record